Celltrion today announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), following ...

Wildfire smoke exposure acutely increased IL-13 expression in NK cells and was negatively associated with COVID-19 vaccine immunity.

Standout combination of complete skin clearance and favorable safety profile in a once daily pill could shift treatment paradigm Nearly half of patients with moderate-to-severe ...

Two-thirds of patients with moderate or severe plaque psoriasis had complete or nearly complete clearance at 4 months with an ...

Shares of Kestra Medical, a wearable cardiac device maker, soared in the company’s public debut this week. Meanwhile, Discord is said to be in ...

Topline results from Phase 3 ICONIC-ADVANCE 1&2�studies show icotrokinra achieved co-primary endpoints and showed superiority to deucravacitinib in moderate-to-severe plaque PsO ...

Until about 20 years ago, systemic treatment options for moderate/severe psoriasis were limited and nonspecific. To get an ...

The FDA had approved Otulfi in September 2024 to treat Crohn’s disease, ulcerative colitis, psoriasis and active psoriatic arthritis. Information on pricing is not yet available.

Investing.com -- The US Food and Drug Administration has accepted GlaxoSmithKline (NYSE: GSK )’s biologics license ...

AI Mobility provider Webus International, steel industry veteran Luda Technology, Chinese ad services provider LZ Technology and ...

We must find a golden middle between nourishing our sense of connection with each other and learning to be comfortable when ...

The stress axis that has been most extensively studied in relation to stress is unquestionably the hypothalamic pituitary ...